Regular ArticlePatent Ductus Arteriosus and Neonatal Death in Prostaglandin Receptor EP4-Deficient Mice☆
References (24)
- et al.
J. Lipid Med. Cell Signal
(1995) - et al.
Prostaglandins
(1994) - et al.
J. Biol. Chem.
(1993) - et al.
Cell
(1995) - et al.
Immunity
(1994) - et al.
J. Pediatr.
(1978) - et al.
J. Pediatr.
(1981) - et al.
Eur. J. Pharmacol.
(1972) - et al.
Eur. J. Pharmacol.
(1985) - et al.
The Pharmacological Basis of Therapeutics
(1985)
Cited by (279)
A biologically active lipid, thromboxane, as a regulator of angiogenesis and lymphangiogenesis
2023, Biomedicine and PharmacotherapyUsing omics to breathe new life into our understanding of the ductus arteriosus oxygen response
2023, Seminars in PerinatologyMolecular mechanisms regulating extracellular matrix-mediated remodeling in the ductus arteriosus
2023, Seminars in PerinatologyPatent Ductus Arteriosus in the Preterm Infant
2023, Avery's Diseases of the NewbornThe roles of eicosanoids in myocardial diseases
2023, Advances in PharmacologyCitation Excerpt :Moreover, EP4 mRNA is strongly expressed in the ductus as shown in situ hybridization study, suggesting the substantial role of the EP4 receptor in the regulation of the patency of this vessel (Segi et al., 1998). These results also indicated that the EP4 receptor is required for the rapid adaptation of the neonatal circulatory system under physiological condition (Segi et al., 1998). Cardiac LOX can be significantly activated under ischemic condition, which promotes leukocytes recruitment to injured cardiac tissues with subsequent elevation of eicosanoids like 5-HETE and 12-HETE (Hughes, Gentry, McGuire, & Taylor, 1991).
- ☆
Gilman, A. G.Goodman, L. S.Rall, T. W.Murad, F.
- 1
To whom correspondence should be addressed. Fax: +81-75-753-4557. E-mail:[email protected].